ArticleMolecular and cellular biology2019
Article in Molecular and cellular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.Oncoimmunology · 2021Trial
- Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA.Pharmaceutical research · 2026Review
- Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.Scientific reports · 2025Article
- Article
- Genetic underpinnings explored: OPA1 deletion and complex phenotypes on chromosome 3q29.BMC medical genomics · 2024Article
- RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping.Life science alliance · 2023Article
- Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.JCI insight · 2023Article
- Transforming RNA-Seq gene expression to track cancer progression in the multi-stage early to advanced-stage cancer development.PloS one · 2023Article
- Ten Years of CRISPRing Cancers In Vitro.Cancers · 2022Review
- Article
- The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ERScience advances · 2022Article
- RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.JCI insight · 2022Article
- Centromere protein E as a novel biomarker and potential therapeutic target for retinoblastoma.Bioengineered · 2021Article
- TargetingCancers · 2021Review
- Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish.Brain : a journal of neurology · 2021Article
- Direct Regulation of DNA Repair by E2F and RB in Mammals and Plants: Core Function or Convergent Evolution?Cancers · 2021Review
- Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.Frontiers in microbiology · 2021Review
- RB Regulates DNA Double Strand Break Repair Pathway Choice by Mediating CtIP Dependent End Resection.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Proliferative control in cancer cells is frequently disrupted by mutations in the retinoblastoma protein (RB) pathway. Intriguingly,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.